Observed a U-shaped association between adiponectin and risk of CVD in AbMole Sibutramine HCl patients with type 2 DM, and indicated that there are differences between diabetic patients and general population in the associations between circulating immune mediators and risk of CVD. What’s more, other two cohort studies did not found any significant association. Schulze et al found that there was an inverse association between adiponectin and risk of CHD in diabetic men, however, it was no longer statistically significant when adjustment for high density lipoprotein cholesterol. They AbMole Alprostadil suggest that HDL cholesterol might partly regulate the relationship between adiponectin concentrations and risk of CHD. Krzyzanowska et al support the idea that no significant association was found between adiponectin and risk of CVD in diabetes patients and assumed that although HMW adiponectin owned anti-inflammatory and anti-atherogenic effects, these effects 
play a more important role in the very early phase of atherogenesis than in manifest macrovascular disease as found in high-risk patients with type 2 DM. The possible limitations of our meta-analysis must be taken into consideration. First, present meta-analysis is based on published results, more detailed combined analysis of studies using individual participant records could help to characterize dose-response relationship, evaluate associations in particular subgroups, compare directly the magnitude of risk association with adiponectin and CVD, allow more complete adjustment for potential confounding factors. Second, sample size or eligible studies in the present study was relatively small and may have insufficient statistical power to detect the marginal association. However, all the included studies were prospective study design, which reduces, to some extent, selection bias and recall bias compared with retrospective studies. Third, the heterogeneity in our results is substantial because our metaanalysis combines data from studies with different charismatics. However, when one study was excluded, the heterogeneity became small. Fourth, publication bias is a potential concern for any meta-analysis based on published studies. The Begg’s test and Egger’s test suggest no publication bias in this met aanalysis, however, the small number of included studies limits the statistical power in these tests. Finally, we did not included unpublished data and it is also possible that we missed some eligible published studies. In conclusion, this systematic review and meta-analysis involved 6 prospective studies and indicated that no association was found between adiponectin concentrations and risk of CVD in type 2 diabetic patients.